The shortest fully active fragment of growth hormone-releasing hormone. Binding the GHRH receptor on pituitary somatotrophs stimulates endogenous GH synthesis and release. Because it acts upstream and preserves negative feedback via somatostatin and IGF-1, the resulting GH release remains pulsatile — mechanistically distinct from administering recombinant GH.
Studied historically as a diagnostic agent for GH reserve and in paediatric GH deficiency. Contemporary use in adults for body composition or “anti-ageing” is not supported by adequate controlled trials.
Formerly FDA-approved as Geref for paediatric GH deficiency; withdrawn from the US market in 2008 for commercial reasons. No currently approved product. Now supplied through compounding, an area under active FDA scrutiny.
Historical trial data showed injection-site reactions and flushing. Long-term consequences of sustained GH-axis stimulation in adults with normal pituitary function are not characterised. Prohibited in sport (WADA S2).
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.